Platelet count measured prior to cancer development is a risk factor for future symptomatic venous thromboembolism: the Tromsø Study.

by Hilde Jensvoll, Kristine Blix, Sigrid K Brækkan, John-Bjarne Hansen
Published 2014-01-01

White blood cell count measured prior to cancer development is associated with future risk of venous thromboembolism--the Tromsø study.

by Kristine Blix, Hilde Jensvoll, Sigrid K Brækkan, John-Bjarne Hansen
Published 2013-01-01

Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000–2014: A Population-based Cohort Study

by Hege S. Haugnes, Helene F. Negaard, Hilde Jensvoll, Tom Wilsgaard, Torgrim Tandstad, Arne Solberg
Published 2021-10-01